Skip to main content

BioShares Biotechnology Products ETF (BBP)

NYSEARCA: BBP · IEX Real-Time Price · USD
52.13 -0.99 (-1.86%)
Sep 24, 2021 4:00 PM EDT - Market closed
Assets$26.06M
NAV$52.13
Expense Ratio0.79%
PE Ration/a
Shares Out500,000
Dividend (ttm)n/a
Dividend Yieldn/a
Ex-Dividend DateDec 20, 2017
1-Year Return
-
Volume263
Open52.43
Previous Close53.11
Day's Range52.13 - 53.11
52-Week Low46.16
52-Week High61.39
Beta1.00
Holdings54
Inception DateDec 17, 2014

About BBP

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration (FDA) for marketing.

Asset ClassPortfolio-Multi Asset
SectorBiotech
RegionNorth America
IssuerBioShares
Stock ExchangeNYSEARCA
Ticker SymbolBBP
Index TrackedBioShares Biotechnology Products Index

Top 10 Holdings

26.94% of assets
NameSymbolWeight
ModernaMRNA4.19%
Travere TherapeuticsTVTX3.09%
BioNTech SEBNTX3.06%
Biohaven PharmaceuticalBHVN2.58%
Blueprint MedicinesBPMC2.42%
ADC Therapeutics SAADCT2.39%
Acceleron PharmaXLRN2.33%
Regeneron PharmaceuticalsREGN2.33%
Harmony BiosciencesHRMY2.30%
Bny Mellon Cash Reserve UsdN/A2.25%
View More Holdings

Dividends

Ex-DividendAmountPay Date
Dec 20, 2017$0.0723Dec 27, 2017
Dec 21, 2015$0.39725Dec 29, 2015
Full Dividend History

News

Beyond Clean Energy, 5 Sector ETFs Soaring to Record Highs

As most corners of the market rallied on the slew of positive news, a few sectors scaled new highs. We have highlighted five ETFs from different sectors that hit all-time highs in the recent trading ses...

Other symbols:ITBPRNXRTXSD
11 months ago - Zacks Investment Research

4 ETFs to Play the Hot Events of Q4

The S&P 500 posted its best third-quarter gains since 2010 with an advancement of 8.5%. The gains could continue as the October-December period is normally gainful for the market.

Other symbols:CLOUONLNPBW
11 months ago - Zacks Investment Research

Top-Performing ETFs of the Worst September Since 2011

After a superb August, September turned gloomy for Wall Street.

Other symbols:DXJSIPOTAN
11 months ago - Zacks Investment Research

5 ETFs Shining Bright Amid September Selling

The combination of lofty valuation, lack of additional fiscal stimulus package, election uncertainty and rising U.S.-China tensions weighed on investors' sentiment.

Other symbols:BETZEDUTIPOTAN
1 year ago - Zacks Investment Research

"Worst September in 18 Years"? 4 Sector ETFs Surviving Selloffs

After a superb August, September looks gloomy for Wall Street. Still,

Other symbols:BETZIBBJPBDRTM
1 year ago - Zacks Investment Research

A Guide to Biotech ETF Investing

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.

1 year ago - Zacks Investment Research

Biotech ETFs Surge on a Flurry of Positive News

The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.

Other symbols:BBCBTECHEPASBIO
1 year ago - Zacks Investment Research

ACADIA Pharmaceuticals Help Lift Biotech ETFs

While the rest of the biotechnology sector remained depressed along with the broader markets, related exchange traded funds found strength from an unexpected surge in ACADIA Pharmaceuticals (NasdaqGS: A...

Other symbols:FBTIBBSBIO
2 years ago - ETF Trends

Biotechnology Market on a Tear: 5 ETFs in Spotlight

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.

Other symbols:ARKGBTECSBIOXBI
2 years ago - Zacks Investment Research

A Spread of Top-Ranked ETFs That Crushed the Market in Q1

We are presenting a bunch of top performing ETFs of the first quarter with a solid Zacks ETF Rank #1 or 2 which are expected to outperform in the quarter ahead.

2 years ago - Zacks Investment Research